ProPhase Labs, Inc. reported a first-quarter 2026 loss as revenue declined sharply from the year-ago quarter amid operational changes in its diagnostics businesses. Revenue was $478K in Q1 2026, and the company recorded a consolidated net loss of $(5.354M), or diluted loss per share of $(0.43).
Financial Highlights
- Revenue: $478K for Q1 2026, down from $1.431M in Q1 2025 (YoY change (66.6%)).
- Net income: Net loss of $(5.354M) for continuing operations in Q1 2026; consolidated net loss was $(5.354M) versus consolidated net income of $3.966M in Q1 2025 (prior year included a discontinued gain).
- Diluted EPS: $(0.43) for Q1 2026, compared with $1.13 in Q1 2025.
Business Highlights
- Revenue and channel shift: The year-over-year revenue decline was driven by lower supplement sales and the cessation of COVID diagnostic services.
- Operational restructuring: Diagnostic subsidiaries stopped testing in May 2025, filed Chapter 11, and the labs were deconsolidated; collection and reorganization efforts are ongoing.
- Genomics & DTC growth: Nebula and DNA Complete continue to offer direct-to-consumer whole genome sequencing, with plans for retail expansion of FDM and university sales.
- Product & IP milestones: BE-Smart™ exceeded a key validation threshold (technical success >95%) and received a U.S. patent; the company plans LDT/RUO commercialization in 2026.
- Pipeline & commercialization: PBIO is advancing Equivir candidates, Linebacker programs and expanding TK Supplements® retail presence while pursuing strategic partnerships and commercialization paths.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.